Agnieszka Cios

Agnieszka Cios

Auto-generated profile, based on publicly available information

Agnieszka Cios

Department of Clinical Pharmacy, Jagiellonian University Medical College, Kraków, Poland.

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
KSKinga Sałat
Kinga Sałat
ACAgnieszka Cios
Agnieszka Cios
Elżbieta WyskaElżbieta Wyska
Elżbieta Wyska
RSRobert Sałat
Robert Sałat
SMSzczepan Mogilski
Szczepan Mogilski
BMBarbara Malawska
Barbara Malawska

5 February 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Joanna Natalia SniecikowskaJoanna Natalia Sniecikowska
Joanna Natalia Sniecikowska
MGMonika Gluch-Lutwin
Monika Gluch-Lutwin
ABAdam Bucki
Adam Bucki
AWAnna Wieckowska
Anna Wieckowska
ASAgata Siwek
Agata Siwek
MKMarcin Kolaczkowski
Marcin Kolaczkowski
Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives were designed as ‘biased agonists’ of serotonin 5-HT1A receptors. Compounds were tested in signal transduction assays (ERK1/2 phosphorylation, cAMP inhibition, Ca2+ mobilization and β-arrestin recruitment) which identified ERK1/2 phosphorylation-preferring aryloxyethyl derivatives. The novel series showed high 5 HT1A receptor affinity, >1000-fold selectivity versus noradrenergic α1, dopamine D2, 5-HT2A, histamine H1 and muscarinic M1 receptors, and favorable drug-likeness properties (CNS-MPO, Fsp3, LELP). The lead structure, (3-chloro-4-fluorophenyl)(4-fluoro-4-(((2-(pyridin-2-yloxy)ethyl)amino)methyl)piperidin-1-yl)methanone (17, NLX-204), displayed high selectivity in the SafetyScreen44™ panel (including hERG channel), high solubility, metabolic stability and Caco-2 penetration, and did not block CYP3A4, CYP2D6 isoenzymes or P-glycoprotein. Preliminary in vivo studies confirmed its promising pharmacokinetic profile. 17 also robustly stimulated ERK1/2 phosphorylation in rat cortex and showed highly potent (MED=0.16 mg/kg) and efficacious antidepressant-like activity, totally eliminating immobility in the rat Porsolt test. These data suggest that the present 5-HT1A receptor biased agonists could constitute promising antidepressant drug candidates.

1 January 2001 in Ceramics International
Verified
Journal Article
Closed access
JSJ. Szymura-Oleksiak
J. Szymura-Oleksiak
AŚA. Ślósarczyk
A. Ślósarczyk
ACA. Cios
A. Cios
BMB. Mycek
B. Mycek
ZPZ. Paszkiewicz
Z. Paszkiewicz
DSD. Stankiewicz
D. Stankiewicz

29 October 2019 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
AWAnna Wesołowska
Anna Wesołowska
MJMagdalena Jastrzębska-Więsek
Magdalena Jastrzębska-Więsek
ACAgnieszka Cios
Agnieszka Cios
APAnna Partyka
Anna Partyka
Introduction: Paliperidone is approved in the United States and Europe for the short- and long-term treatment of schizophrenia in adults and adolescents as well as for the acute treatment of schizoaffective disorder either as monotherapy or adjunctive therapy to mood stabilizers and/or antidepressants. It is recommended in patients with hepatic impairment and evokes less drug–drug interactions. Areas covered: This review article focuses on the preclinical discovery of paliperidone, the major active metabolite of risperidone. It provides details regarding paliperidone’s pharmacological and neurochemical mechanisms, and their contribution to therapeutic benefits and adverse effects, based on the available literature with respect to the preclinical and clinical findings and product labels. Expert opinion: Paliperidone exhibits a high affinity and antagonistic activity toward D2 and 5-HT2A receptors, followed by 5-HT7, H1, α1, and α2 receptors. In preclinical studies, paliperidone produces antidepressant, anxiolytic, mood-stabilizing, analgesic actions, and affects the endocannabinoid system. It is also known to evoke procognitive, antioxidant, and anti-inflammatory activities. Its positive activity on neurogenesis, neuronal, and synaptic plasticity deserves to be emphasized. The clinical superiority of paliperidone is based primarily on the available formulations of the drug rather than in the subtle differences in its pharmacokinetic/pharmacodynamic properties compared to risperidone.

1 September 2014 in Experimental Gerontology
Verified
Journal Article
Closed access
ACAgnieszka Cios
Agnieszka Cios
Elżbieta WyskaElżbieta Wyska
Elżbieta Wyska
JSJoanna Szymura-Oleksiak
Joanna Szymura-Oleksiak
TGTomasz Grodzicki
Tomasz Grodzicki

Verified
Journal Article
Open access
PDF file
SSSylwia Sudoł-Tałaj
Sylwia Sudoł-Tałaj
ACAgnieszka Cios
Agnieszka Cios
MJMagdalena Jastrzebska-Wiesek
Magdalena Jastrzebska-Wiesek
EHEwelina Barbara Honkisz-Orzechowska
Ewelina Barbara Honkisz-Orzechowska
BMBarbara Mordyl
Barbara Mordyl
JHJadwiga Handzlik
Jadwiga Handzlik
Among the serotonin receptors, one of the most recently discovered 5-HT6 subtype is an important protein target and its ligands may play a key role in the innovative treatment of cognitive disorders. However, none of its selective ligands have reached the pharmaceutical market yet. Recently, a new chemical class of potent 5-HT6 receptor agents, the 1,3,5-triazine-piperazine derivatives, has been synthesized. Three members, the ortho and meta dichloro- (1,2) and the unsubstituted phenyl (3) derivatives, proved to be of special interest due to their high affinities (1,2) and selectivity (3) toward 5-HT6 receptor. Thus, a broader pharmacological profile for 1–3, including comprehensive screening of the receptor selectivity and drug-like parameters in vitro as well as both, pharmacokinetic and pharmacodynamic properties in vivo, have been investigated within this study. A comprehensive analysis of the obtained results indicated significant procognitive-like activity together with beneficial drug-likeness in vitro and pharmacokinetics in vivo profiles for both, (RS)-4-[1-(2,3-dichlorophenoxy)propyl]-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (2) and (RS)-4-(4-methylpiperazin-1-yl)-6-(1-phenoxypropyl)-1,3,5-triazin-2-amine (3), but insensibly predominant for compound 2. Nevertheless, both compounds (2 and 3) seem to be good Central Nervous System drug candidates in search for novel therapeutic approach to dementia diseases, based on the 5-HT6 receptor target.